Altimmune Announces Positive Topline Results from the IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH
First product candidate to demonstrate significant MASH effects and weight loss at 24 weeks Trial met its primary endpoint with...
Month: June 2025
CRISPR Therapeutics Reports Positive Additional Phase 1 Data for CTX310™ Targeting ANGPTL3 and Provides Update on In Vivo Cardiovascular Pipeline
-New Phase 1 clinical data for CTX310™ continues to demonstrate dose-dependent reductions in triglycerides (TG) and low-density lipoprotein (LDL), with...
XORTX Announces USD $925,000 Private Placement
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES CALGARY, Alberta, June 26,...
Medicenna Therapeutics Reports Fiscal Year 2025 Financial Results and Operational Highlights
Updated cash guidance provides runway into at least mid-2026 MDNA11 Phase 1/2 clinical trial on track for data readouts in...
Revive Therapeutics Nears Completion of Key Nerve Agent Countermeasure Study with Canadian Department of National Defence Highlighting Significant Stockpiling Opportunity
TORONTO, June 26, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a...
Tilray Medical Publishes Pioneering Research on the Pharmacokinetics of THC and CBD Formulations
New Study Provides Insight into the Bioavailability of Medical Cannabis Formulations for Therapeutic TreatmentNEW YORK, June 26, 2025 (GLOBE NEWSWIRE)...
Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia
Study met its primary and key secondary endpoints, demonstrating rapid and sustained improvement in near visual acuitySafety profile consistent with...
ProFound Therapeutics Announces Multi-Year Strategic Collaboration with Novartis to Discover and Develop Novel Therapeutics for Cardiovascular Disease
ProFound to receive $25M in upfront and near-term milestone payments with a potential value from downstream milestones of $750M per...
I-Mab Highlights Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025
71% objective response rate (ORR) (12/17) per RECIST v1.1, with a favorable safety profile 83% ORR (10/12) in patients across...
World No. 1 Tennis Star Aryna Sabalenka Joins Prenetics’ IM8 Health as Global Ambassador and Shareholder
Aryna Sabalenka becomes first-ever current athlete shareholder in Prenetics, listed on the NASDAQ: (PRE)In just six months, IM8 is one...
Alvotech’s Lenders Lower Interest on Senior Secured Term Loan Facility
REYKJAVIK, ICELAND (June 26, 2025) — Alvotech (NASDAQ: ALVO, ALVO SDB, the “Company”), a global biotech company specializing in the...
Alvotech’s Lenders Lower Interest on Senior Secured Term Loan Facility
REYKJAVIK, Iceland, June 26, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO, the “Company”), a global biotech company specializing in the...
First market launch of the adrenaline nasal spray, EURneffy®, for treatment of adults and children in Germany
ALK (ALKB:DC / OMX: ALK B) today announced the first market launch of EURneffy® 2 mg (the trade name for neffy® in...
Bavarian Nordic Announces the Initiation of Clinical Trials of Mpox Vaccine in Infants and Pregnant Women
First studies to evaluate MVA-BN in infants under 2 years of age and pregnant and breastfeeding women.The multi-partner research project...
26 ZAZA THCA Flower Strains Unleashed: The Hemp Doctor’s Largest Drop Yet
MOORESVILLE, N.C., June 26, 2025 (GLOBE NEWSWIRE) -- The Hemp Doctor, America’s premier hemp and cannabinoid brand, introduces its largest...
Valneva Announces Exclusive Vaccine Marketing and Distribution Agreement for Germany with CSL Seqirus
Saint-Herblain, France, June 26, 2025 – Valneva SE, (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced an...
Hummingbird Bioscience Licenses HMBD-002, Phase II-Ready Anti-VISTA Monoclonal Antibody to Percheron Therapeutics
Percheron Therapeutics obtains exclusive worldwide rights to Hummingbird Bioscience’s anti-VISTA mAb for further clinical development Hummingbird Bioscience stands to receive...
Altimmune to Announce Topline 24 Week Results from its IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH on Thursday, June 26
Company to host Investor Webcast on Thursday, June 26, 2025, at 8:30 am E.T.GAITHERSBURG, Md., June 25, 2025 (GLOBE NEWSWIRE)...
Rakovina Therapeutics Announces Results from 2025 Annual General Meeting
VANCOUVER, British Columbia, June 25, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (“Rakovina” or the “Company”),...
Global Orthodontists Gather in China to Explore Smartee’s Mandibular Repositioning Technology
XI'AN, China , June 26, 2025 /PRNewswire/ -- Smartee Denti-Technology recently hosted international orthodontic experts and partners at a global symposium...